Mode
Text Size
Log in / Sign up

Pilot RCT of mHealth intervention in adult elective cardiac surgery patients showed feasibility and acceptable uptake.

Pilot RCT of mHealth intervention in adult elective cardiac surgery patients showed feasibility and …
Photo by Navy Medicine / Unsplash
Key Takeaway
Note this pilot RCT showed feasibility but readmission differences were not reported.

This pilot randomized controlled trial evaluated an mHealth intervention in adult elective cardiac surgery patients discharged home within 30 days. Eligible participants were able to understand spoken English and use a smartphone, tablet, or computer. The setting was a major metropolitan publicly funded health service. A total of 70 eligible patients were identified, and 61 participated in the study.

The intervention comprised patient narrative videos and online resources focused on diagnosis, preparing for surgery, and immediate and ongoing recovery. The primary outcomes assessed were feasibility, acceptability, and protocol integrity. Secondary outcomes included 30-day readmission, quality of life, knowledge, skill, and confidence for self-help. The follow-up period covered 30-day readmission and 90-day follow-up.

Feasibility and acceptability were feasible and acceptable for patients, with no protocol violations observed. Of the 61 participants, 27 (84.4%) accessed the intervention. Content viewing showed high engagement with material related to diagnosis, surgery, and looking forward, compared with programs related to rehabilitation. Actions for self-help incrementally increased from baseline to 90-day follow-up in the intervention group.

Safety data regarding adverse events, serious adverse events, discontinuations, and tolerability were not reported. The study limitations include modest uptake of the mHealth intervention and its pilot nature. The effect of patient narratives on patient activation warrants testing in an adequately powered randomized controlled trial.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
AIMS: To determine feasibility, acceptability and test protocol integrity, for testing a mobile health (mHealth) intervention focused on enhancing self-management after adult cardiac surgery. Secondary aims were to assess the effect of the intervention on 30-day readmission, quality of life, and knowledge, skill and confidence for self-help. METHODS AND RESULTS: A parallel-group, pilot randomized controlled trial was conducted in a major metropolitan publicly funded health service. Adult elective cardiac surgery patients discharged home within 30-days, able to understand spoken English, and use a smartphone, tablet or computer were eligible for inclusion. The mHealth intervention comprised patient narrative videos, and on-line resources focused on diagnosis, preparing for surgery, and immediate, and ongoing recovery. From August 2021 until the 23rd of December 2022, there were 341/516 elective cardiac surgery cases. Of 70 (20.5%) eligible patients, 61 (87.1%) participated. The mHealth intervention was accessed by 27 (84.4%) participants. When accessed, the intervention was feasible and acceptable for patients, there were no protocol violations. There was high viewing of content related to diagnosis, surgery and looking forward, compared with programmes related to rehabilitation. Readmission rates did not differ between groups. Participants taking action to manage their health in the intervention group incrementally increased from baseline to 90-day follow-up. CONCLUSION: The effect of patient narratives on patient activation warrants testing in an adequately powered randomized controlled trial. While the uptake of the mHealth intervention was modest, trends in actions for self-help and rate of 30-day readmission imply the intervention is potentially effective in improving self-help management. REGISTRATION: The Australian and New Zealand Clinical Trials Registry: ACTRN12621000082808.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.